Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_962794626a937783f7c684670eba23e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e04a9c30b01a6909696dc92e883f241c |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 |
filingDate |
2018-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ff30f867635771a270852078a32905e |
publicationDate |
2018-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2018159845-A1 |
titleOfInvention |
Preventive or therapeutic agent for htlv-1-associated myelopathy using low-dose anti-ccr4 antibody |
abstract |
The purpose of the present invention is to provide a novel therapeutic or preventive agent for human T-cell leukemia virus-1-associated myelopathy (HAM), characterized by containing an anti-human CC-chemokine receptor 4 (CCR4) antibody or a fragment of the antibody as an active ingredient and by a dosage regimen of said antibody or of a fragment of the antibody. The present invention pertains to a therapeutic or preventative agent for HAM, which is characterized by containing an anti-human CCR4 antibody or a fragment of the antibody as an active ingredient and in that the antibody or fragment of the antibody is administered at a low dose. |
priorityDate |
2017-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |